BI-3406:一种强效选择性SOS1-KRAS相互作用抑制剂,通过联合MEK抑制在KRAS驱动癌症中有效
KRAS是胰腺癌、结直肠癌和非小细胞肺癌中最常见的突变驱动基因,直接靶向KRAS困难,而抑制下游RAF-MEK-ERK通路因反馈激活效果有限。研究者发现口服生物利用度好的选择性SOS1抑制剂BI-3406,可结合SOS1催化结构域阻止其与KRAS相互作用,减少GTP负载RAS形成并抑制多种KRAS驱动癌症增殖,还能减弱MEK抑制剂引起的反馈再激活,增强对MEK抑制的敏感性。联合SOS1和MEK抑制为KRAS驱动肿瘤提供了新治疗概念,包括常见突变G12D、G12V、G12C和G13D。
要点
- BI-3406是口服生物利用的选择性SOS1抑制剂,阻断SOS1与KRAS结合。
- BI-3406减少GTP负载RAS形成,抑制多种KRAS驱动癌症的细胞增殖。
- BI-3406减弱MEK抑制剂诱导的反馈再激活,联合MEK抑制增强疗效。
核心结论
- 联合SOS1和MEK抑制是治疗KRAS驱动肿瘤的新颖有效治疗概念。
研究设计与样本
- 临床前研究,发现并表征小分子SOS1抑制剂BI-3406的活性及与MEK抑制剂的联合效果。
主要发现
- BI-3406结合SOS1催化结构域,阻止其与KRAS相互作用。
- BI-3406减少GTP负载RAS形成,限制广泛KRAS驱动癌症的细胞增殖。
- BI-3406减弱MEK抑制剂诱导的反馈再激活,增强KRAS依赖癌症对MEK抑制的敏感性。
临床怎么用
- 对于KRAS突变癌症(包括G12D、G12V、G12C和G13D),可考虑SOS1抑制剂联合MEK抑制的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non-small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF-MEK-ERK cascade, has shown limited success because of activation of feedback networks that keep the pathway in check. We hypothesized that inhibiting SOS1, a KRAS activator and important feedback node, represents an effective approach to treat KRAS-driven cancers. We report the discovery of a highly potent, selective, and orally bioavailable small-molecule SOS1 inhibitor, BI-3406, that binds to the catalytic domain of SOS1, thereby preventing the interaction with KRAS. BI-3406 reduces formation of GTP-loaded RAS and limits cellular proliferation of a broad range of KRAS-driven cancers. Importantly, BI-3406 attenuates feedback reactivation induced by MEK inhibitors and thereby enhances sensitivity of KRAS-dependent cancers to MEK inhibition. Combined SOS1 and MEK inhibition represents a novel and effective therapeutic concept to address KRAS-driven tumors. SIGNIFICANCE: To date, there are no effective targeted pan-KRAS therapies. In-depth characterization of BI-3406 activity and identification of MEK inhibitors as effective combination partners provide an attractive therapeutic concept for the majority of KRAS-mutant cancers, including those fueled by the most prevalent mutant KRAS oncoproteins, G12D, G12V, G12C, and G13D.See related commentary by Zhao et al., p. 17.This article is highlighted in the In This Issue feature, p. 1.
引用
- Hofmann MH, Gmachl M, Ramharter J, et al. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discov. 2020. PMID: 32816843. doi:10.1158/2159-8290.CD-20-0142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。